What is Global Hydroxychloroquine Sulphate Market?
The Global Hydroxychloroquine Sulphate Market is a comprehensive study of the worldwide market trends and growth prospects. This market, which is primarily used in the treatment of malaria, lupus erythematosus, and rheumatoid arthritis, has seen a significant surge in demand due to the ongoing global health crisis. The market was valued at US$ 879.4 million in 2022 and is expected to reach a value of US$ 1004.8 million by 2029. This indicates a Compound Annual Growth Rate (CAGR) of 1.9% during the forecast period of 2023-2029. The market is dominated by major producers such as Sanofi, Novartis, and Shanghai Zhongxisanwei, who held revenue ratios of 36.07%, 14.20%, and 15.08% respectively in 2019.
100mg, 200mg, Others in the Global Hydroxychloroquine Sulphate Market:
The Global Hydroxychloroquine Sulphate Market is segmented based on the dosage of the drug, primarily into 100mg, 200mg, and others. Each dosage has its own set of applications and is prescribed based on the severity of the disease and the patient's overall health condition. The 100mg dosage is usually prescribed for mild cases or as a preventive measure, while the 200mg dosage is used for more severe cases. The 'others' category includes dosages that are customized based on specific patient needs. The demand for each dosage type varies based on the prevalence of the diseases it treats and the recommendations of health organizations.
Lupus Erythematosus, Rheumatoid Arthritis, Others in the Global Hydroxychloroquine Sulphate Market:
The usage of Hydroxychloroquine Sulphate is widespread in the treatment of Lupus Erythematosus, Rheumatoid Arthritis, and other diseases. Lupus Erythematosus is a long-term autoimmune disease where the body's immune system becomes hyperactive and attacks normal, healthy tissue. Rheumatoid Arthritis is a chronic inflammatory disorder affecting many joints, including those in the hands and feet. Hydroxychloroquine Sulphate is used to reduce inflammation and help prevent these diseases from progressing. The 'others' category includes diseases and conditions that are less common but can still benefit from the use of Hydroxychloroquine Sulphate. The demand in each of these areas is influenced by the prevalence of the disease and the effectiveness of the drug in managing it.
Global Hydroxychloroquine Sulphate Market Outlook:
The outlook for the Global Hydroxychloroquine Sulphate Market is promising, with a steady growth rate projected for the coming years. The market was valued at US$ 879.4 million in 2022 and is expected to reach US$ 1004.8 million by 2029, growing at a CAGR of 1.9% during the forecast period of 2023-2029. The market is dominated by major producers such as Sanofi, Novartis, and Shanghai Zhongxisanwei, who held revenue ratios of 36.07%, 14.20%, and 15.08% respectively in 2019. These companies have a strong presence in the market and are expected to continue to play a significant role in the market's growth.
| Report Metric | Details |
| Report Name | Hydroxychloroquine Sulphate Market |
| Accounted market size in 2022 | US$ 879.4 million |
| Forecasted market size in 2029 | US$ 1004.8 million |
| CAGR | 1.9% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Sanofi, Novartis, Shanghai Zhongxisanwei, Teva, Zydus Cadila, Mylan, Apotex, Advanz Pharma, Sun Pharma, Kyung Poong, Ipca Laboratories, Hanlim Pharmaceutical, Bristol Laboratories |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
